Inactive Instrument
Anacor Pharmaceuticals Inc Stock
Stocks
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Nasdaq
|
||
| - USD | - |
|
| 16-05-26 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 16-05-16 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Tech/Sci/R&D Officer | 79 | 2004-01-31 | |
Margaret Madden
PRN | Corporate Officer/Principal | - | 2016-06-23 |
| General Counsel | 77 | 2009-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Margaret Madden
BRD | Director/Board Member | - | 2016-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 2016-06-23 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | -0.36% | +49.37% | +94.17% | 71.53B | |
| -0.19% | +1.32% | +37.20% | +83.85% | 60.12B | |
| -1.51% | +2.39% | +9.10% | +35.15% | 48.85B | |
| -0.05% | +0.37% | +41.54% | +36.65% | 44.28B | |
| +0.38% | +7.61% | +339.53% | +641.55% | 43.83B | |
| +0.18% | +0.26% | +7.41% | +103.45% | 41.53B | |
| -0.67% | +0.17% | +7.60% | +46.37% | 30.13B | |
| +4.77% | +6.16% | +36.77% | +22.78% | 27.98B | |
| -1.29% | -3.55% | -20.74% | +352.04% | 25.25B | |
| Average | +0.64% | +1.18% | +56.42% | +157.33% | 43.72B | |
| Weighted average by Cap. | +0.80% | +1.37% | +60.93% | +148.55% |
- Stock Market
- Stocks
- Stock
Select your edition
All financial news and data tailored to specific country editions
